News
Amgen, AZ’s asthma drug tezepelumab scores phase III win
Amgen and AstraZeneca’s (AZ) experimental asthma drug tezepelumab has scored a phase III win in severe, uncontrolled asthma.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Amgen and AstraZeneca’s (AZ) experimental asthma drug tezepelumab has scored a phase III win in severe, uncontrolled asthma.